ASIA PACIFIC BIOCHIP MARKET FORECAST 2018-2026
KEY FINDINGS
The revenue generated by the Asia-Pacific biochip market is expected to progress with an estimated CAGR of 21.13% between the forecast years of 2018-2026.
MARKET INSIGHTS
Technological advancement in biotechnology, rising number of applications for biochips and the overall scope for biotechnological growth in the sub-continent of Asia are factors that are presenting the market with immense opportunities to expand.
Asia will see high growth due to new strategies by biotechnology companies including launch products in Asia by countries like China and South Korea before FDA or E.U. approvals. China
China biochip market accounted for the highest revenue share in 2017, and the countries is expected to showcase similar growth pattern throughout the forecast period. Other significant markets in this region are Japan, India, South Korea, Australia and those in the rest of Asia-Pacific. However, the complexities of biological systems, high costs of instruments and a lack of common regulatory standards are factors that might challenge this market’s growth in the future.
COMPETITIVE INSIGHTS
Some of the established players in this market are Bio-Rad Laboratories Inc, Samsung Electronics Inc, Illumina Inc, Origene Technologies Inc, Cybrdi Inc, Biomerieux SA, Fluidigm Corporation, Agilent Technology Inc, Biochain Institute Inc, Thermo Fisher Scientific Inc, and Perkinelmer Inc.
The revenue generated by the Asia-Pacific biochip market is expected to progress with an estimated CAGR of 21.13% between the forecast years of 2018-2026.
MARKET INSIGHTS
Technological advancement in biotechnology, rising number of applications for biochips and the overall scope for biotechnological growth in the sub-continent of Asia are factors that are presenting the market with immense opportunities to expand.
Asia will see high growth due to new strategies by biotechnology companies including launch products in Asia by countries like China and South Korea before FDA or E.U. approvals. China
China biochip market accounted for the highest revenue share in 2017, and the countries is expected to showcase similar growth pattern throughout the forecast period. Other significant markets in this region are Japan, India, South Korea, Australia and those in the rest of Asia-Pacific. However, the complexities of biological systems, high costs of instruments and a lack of common regulatory standards are factors that might challenge this market’s growth in the future.
COMPETITIVE INSIGHTS
Some of the established players in this market are Bio-Rad Laboratories Inc, Samsung Electronics Inc, Illumina Inc, Origene Technologies Inc, Cybrdi Inc, Biomerieux SA, Fluidigm Corporation, Agilent Technology Inc, Biochain Institute Inc, Thermo Fisher Scientific Inc, and Perkinelmer Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC IS THE FASTEST EVOLVING REGIONAL MARKET
3.2.2. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF THE BIOCHIPS MARKET BY TYPE SEGMENT
3.2.3. HOSPITALS & DIAGNOSTICS CENTERS – KEY END USER VERTICAL
3.2.4. PROTEIN CHIP IN THE TYPE SEGMENT IS PROJECTED TO RISE WITH THE HIGHEST GROWTH RATE
4. MARKET DYNAMICS
4.1. PARENT MARKET ANALYSIS: GENOMICS AND PROTEOMICS MARKET
4.2. ETYMOLOGY OF BIOCHIPS MARKET
4.3. MARKET DEFINITION & SCOPE
4.4. DRIVERS
4.4.1. INCREASING PREVALENCE OF CANCER
4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
4.5. RESTRAINTS
4.5.1. LACK OF HEALTHCARE COVERAGE
4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
4.5.3. LACK OF AWARENESS ABOUT BIOCHIP TECHNOLOGY
4.6. OPPORTUNITIES
4.6.1. TECHNOLOGICAL ADVANCEMENT IN BIOTECHNOLOGY
4.6.2. IMMENSE GROWTH OPPORTUNITIES IN THE SUB-CONTINENT OF ASIA
4.6.3. GROWING APPLICATIONS OF BIOCHIPS
4.7. CHALLENGES
4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
4.7.2. LACK OF COMMON REGULATORY STANDARDS
4.7.3. HIGH INSTRUMENTATION COST
5. MARKET BY TYPE
5.1. DNA CHIPS
5.1.1. AGRICULTURAL BIOTECHNOLOGY
5.1.2. CANCER DIAGNOSTICS & TREATMENT
5.1.3. DRUG DISCOVERY
5.1.4. GENE EXPRESSION
5.1.5. GENOMICS
5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
5.1.7. OTHER DNA CHIPS
5.2. LAB ON A CHIP
5.2.1. CLINICAL DIAGNOSTICS
5.2.2. DRUG DISCOVERY
5.2.3. GENOMICS
5.2.4. POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS)
5.2.5. PROTEOMICS
5.2.6. OTHER LAB ON A CHIP
5.3. PROTEIN CHIPS
5.3.1. DIAGNOSTICS
5.3.2. DRUG DISCOVERY
5.3.3. EXPRESSION PROFILING
5.3.4. HIGH THROUGHPUT SCREENING
5.3.5. PROTEOMICS
5.3.6. OTHER PROTEIN CHIPS
5.4. OTHER CHIPS
5.4.1. CELL ARRAYS
5.4.2. TISSUE ARRAYS
6. MARKET BY SUBSTRATE MATERIALS
6.1. GLASS
6.2. POLYMERS
6.3. SILICON
6.4. OTHER SUBSTRATE MATERIALS
7. MARKET BY END USERS
7.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.2. HOSPITALS AND DIAGNOSTICS CENTERS
7.3. ACADEMIC AND RESEARCH INSTITUTE
8. KEY ANALYTICS
8.1. PORTERS FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. RESEARCH & DEVELOPMENT
8.4.2. RAW MATERIALS
8.4.3. MANUFACTURING
8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
8.4.5. END USERS
8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
8.6. KEY BUYING CRITERIA
8.6.1. COST
8.6.2. APPLICATIONS
8.6.3. PRODUCT TYPE
8.7. INVESTMENT ANALYSIS
8.7.1. OPPORTUNITIES BY END-USER SEGMENT
8.7.2. OPPORTUNITIES BY BIOCHIP TYPE SEGMENT
9. GEOGRAPHICAL ANALYSIS
9.1. CHINA
9.2. JAPAN
9.3. INDIA
9.4. SOUTH KOREA
9.5. AUSTRALIA
9.6. REST OF ASIA PACIFIC
10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. KEY COMPANY ANALYSIS
10.2.1. MERCK GMBH
10.2.2. AGILENT TECHNOLOGY INC.
10.2.3. ILLUMINA INC.
10.2.4. THERMO FISHER SCIENTIFIC INC.
10.3. CORPORATE STRATEGIES
10.3.1. PARTNERSHIP & COLLABORATION
10.3.2. MERGERS AND ACQUISITIONS
10.4. COMPANY PROFILES
10.4.1. AGILENT TECHNOLOGY INC.
10.4.2. BIOCHAIN INSTITUTE INC.
10.4.3. BIOMERIEUX SA
10.4.4. BIO-RAD LABORATORIES INC.
10.4.5. CEPHEID INC.
10.4.6. CYBRDI INC.
10.4.7. FLUIDIGM CORPORATION
10.4.8. GAMIDA FOR LIFE GROUP
10.4.9. ILLUMINA INC.
10.4.10. IMGENEX
10.4.11. MERCK GMBH
10.4.12. ORIGENE TECHNOLOGIES INC.
10.4.13. PERKINELMER INC.
10.4.14. SAMSUNG ELECTRONICS INC.
10.4.15. THERMO FISHER SCIENTIFIC INC.
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC IS THE FASTEST EVOLVING REGIONAL MARKET
3.2.2. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF THE BIOCHIPS MARKET BY TYPE SEGMENT
3.2.3. HOSPITALS & DIAGNOSTICS CENTERS – KEY END USER VERTICAL
3.2.4. PROTEIN CHIP IN THE TYPE SEGMENT IS PROJECTED TO RISE WITH THE HIGHEST GROWTH RATE
4. MARKET DYNAMICS
4.1. PARENT MARKET ANALYSIS: GENOMICS AND PROTEOMICS MARKET
4.2. ETYMOLOGY OF BIOCHIPS MARKET
4.3. MARKET DEFINITION & SCOPE
4.4. DRIVERS
4.4.1. INCREASING PREVALENCE OF CANCER
4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
4.5. RESTRAINTS
4.5.1. LACK OF HEALTHCARE COVERAGE
4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
4.5.3. LACK OF AWARENESS ABOUT BIOCHIP TECHNOLOGY
4.6. OPPORTUNITIES
4.6.1. TECHNOLOGICAL ADVANCEMENT IN BIOTECHNOLOGY
4.6.2. IMMENSE GROWTH OPPORTUNITIES IN THE SUB-CONTINENT OF ASIA
4.6.3. GROWING APPLICATIONS OF BIOCHIPS
4.7. CHALLENGES
4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
4.7.2. LACK OF COMMON REGULATORY STANDARDS
4.7.3. HIGH INSTRUMENTATION COST
5. MARKET BY TYPE
5.1. DNA CHIPS
5.1.1. AGRICULTURAL BIOTECHNOLOGY
5.1.2. CANCER DIAGNOSTICS & TREATMENT
5.1.3. DRUG DISCOVERY
5.1.4. GENE EXPRESSION
5.1.5. GENOMICS
5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
5.1.7. OTHER DNA CHIPS
5.2. LAB ON A CHIP
5.2.1. CLINICAL DIAGNOSTICS
5.2.2. DRUG DISCOVERY
5.2.3. GENOMICS
5.2.4. POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS)
5.2.5. PROTEOMICS
5.2.6. OTHER LAB ON A CHIP
5.3. PROTEIN CHIPS
5.3.1. DIAGNOSTICS
5.3.2. DRUG DISCOVERY
5.3.3. EXPRESSION PROFILING
5.3.4. HIGH THROUGHPUT SCREENING
5.3.5. PROTEOMICS
5.3.6. OTHER PROTEIN CHIPS
5.4. OTHER CHIPS
5.4.1. CELL ARRAYS
5.4.2. TISSUE ARRAYS
6. MARKET BY SUBSTRATE MATERIALS
6.1. GLASS
6.2. POLYMERS
6.3. SILICON
6.4. OTHER SUBSTRATE MATERIALS
7. MARKET BY END USERS
7.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.2. HOSPITALS AND DIAGNOSTICS CENTERS
7.3. ACADEMIC AND RESEARCH INSTITUTE
8. KEY ANALYTICS
8.1. PORTERS FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. RESEARCH & DEVELOPMENT
8.4.2. RAW MATERIALS
8.4.3. MANUFACTURING
8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
8.4.5. END USERS
8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
8.6. KEY BUYING CRITERIA
8.6.1. COST
8.6.2. APPLICATIONS
8.6.3. PRODUCT TYPE
8.7. INVESTMENT ANALYSIS
8.7.1. OPPORTUNITIES BY END-USER SEGMENT
8.7.2. OPPORTUNITIES BY BIOCHIP TYPE SEGMENT
9. GEOGRAPHICAL ANALYSIS
9.1. CHINA
9.2. JAPAN
9.3. INDIA
9.4. SOUTH KOREA
9.5. AUSTRALIA
9.6. REST OF ASIA PACIFIC
10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. KEY COMPANY ANALYSIS
10.2.1. MERCK GMBH
10.2.2. AGILENT TECHNOLOGY INC.
10.2.3. ILLUMINA INC.
10.2.4. THERMO FISHER SCIENTIFIC INC.
10.3. CORPORATE STRATEGIES
10.3.1. PARTNERSHIP & COLLABORATION
10.3.2. MERGERS AND ACQUISITIONS
10.4. COMPANY PROFILES
10.4.1. AGILENT TECHNOLOGY INC.
10.4.2. BIOCHAIN INSTITUTE INC.
10.4.3. BIOMERIEUX SA
10.4.4. BIO-RAD LABORATORIES INC.
10.4.5. CEPHEID INC.
10.4.6. CYBRDI INC.
10.4.7. FLUIDIGM CORPORATION
10.4.8. GAMIDA FOR LIFE GROUP
10.4.9. ILLUMINA INC.
10.4.10. IMGENEX
10.4.11. MERCK GMBH
10.4.12. ORIGENE TECHNOLOGIES INC.
10.4.13. PERKINELMER INC.
10.4.14. SAMSUNG ELECTRONICS INC.
10.4.15. THERMO FISHER SCIENTIFIC INC.
LIST OF TABLES
TABLE 1: ASIA PACIFIC BIOCHIPS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
TABLE 3: ASIA PACIFIC BIOCHIPS MARKET, BY TYPE, 2018-2026, (IN $ MILLION)
TABLE 4: ASIA PACIFIC DNA CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 5: ASIA PACIFIC LAB ON A CHIP MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 6: ASIA PACIFIC PROTEIN CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 7: ASIA PACIFIC OTHER CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 8: ASIA PACIFIC BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
TABLE 9: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
TABLE 10: ASIA PACIFIC BIOCHIPS MARKET, BY END USERS, 2018-2026 (IN $ MILLIONS)
TABLE 11: OPPORTUNITY MATRIX FOR BIOCHIPS MARKET
TABLE 12: VENDOR LANDSCAPE OF BIOCHIPS MARKET
TABLE 13: LEGAL, POLICY & REGULATORY FRAMEWORK OF BIOCHIPS MARKET
TABLE 14: ASIA PACIFIC BIOCHIPS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
TABLE 15: LIST OF PARTNERSHIP & COLLABORATION
TABLE 16: LIST OF MERGERS AND ACQUISITIONS
TABLE 1: ASIA PACIFIC BIOCHIPS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
TABLE 3: ASIA PACIFIC BIOCHIPS MARKET, BY TYPE, 2018-2026, (IN $ MILLION)
TABLE 4: ASIA PACIFIC DNA CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 5: ASIA PACIFIC LAB ON A CHIP MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 6: ASIA PACIFIC PROTEIN CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 7: ASIA PACIFIC OTHER CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 8: ASIA PACIFIC BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
TABLE 9: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
TABLE 10: ASIA PACIFIC BIOCHIPS MARKET, BY END USERS, 2018-2026 (IN $ MILLIONS)
TABLE 11: OPPORTUNITY MATRIX FOR BIOCHIPS MARKET
TABLE 12: VENDOR LANDSCAPE OF BIOCHIPS MARKET
TABLE 13: LEGAL, POLICY & REGULATORY FRAMEWORK OF BIOCHIPS MARKET
TABLE 14: ASIA PACIFIC BIOCHIPS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
TABLE 15: LIST OF PARTNERSHIP & COLLABORATION
TABLE 16: LIST OF MERGERS AND ACQUISITIONS
LIST OF FIGURES
FIGURE 1: ASIA PACIFIC BIOCHIPS MARKET, BY END USERS, 2017 & 2026 (IN %)
FIGURE 2: ASIA PACIFIC BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 3: EVOLUTION & TRANSITION OF BIOCHIPS
FIGURE 4: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
FIGURE 5: COMPARISON OF HEALTHCARE SPENDING PER CAPITA AND OUT OF THE POCKET HEALTH EXPENDITURE
FIGURE 6: ASIA PACIFIC BIOCHIPS MARKET, BY DNA CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2018-2026 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2018-2026 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC DNA CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC DNA CHIPS MARKET, BY GENE EXPRESSION, 2018-2026 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC DNA CHIPS MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2018-2026 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC DNA CHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC BIOCHIPS MARKET, BY LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC LAB ON A CHIP MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS), 2018-2026 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC LAB ON A CHIP MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 20: ASIA PACIFIC LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC BIOCHIPS MARKET, BY PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 24: ASIA PACIFIC PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2018-2026 (IN $ MILLION)
FIGURE 25: ASIA PACIFIC PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2018-2026 (IN $ MILLION)
FIGURE 26: ASIA PACIFIC PROTEIN CHIPS MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 27: ASIA PACIFIC PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 28: ASIA PACIFIC BIOCHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 29: ASIA PACIFIC OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 30: ASIA PACIFIC OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 31: ASIA PACIFIC BIOCHIPS MARKET, BY GLASS, 2018-2026 (IN $ MILLIONS)
FIGURE 32: ASIA PACIFIC BIOCHIPS MARKET, BY POLYMERS, 2018-2026 (IN $ MILLIONS)
FIGURE 33: ASIA PACIFIC BIOCHIPS MARKET, BY SILICON, 2018-2026 (IN $ MILLIONS)
FIGURE 34: ASIA PACIFIC BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
FIGURE 35: ASIA PACIFIC BIOCHIPS MARKET, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2026 (IN $ MILLIONS)
FIGURE 36: ASIA PACIFIC BIOCHIPS MARKET, BY HOSPITALS AND DIAGNOSTICS CENTERS, 2018-2026 (IN $ MILLIONS)
FIGURE 37: ASIA PACIFIC BIOCHIPS MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2018-2026 (IN $ MILLIONS)
FIGURE 38: PORTER’S FIVE FORCE MODEL OF BIOCHIPS MARKET
FIGURE 39: VALUE CHAIN OF BIOCHIPS MARKET
FIGURE 40: KEY IMPACT ANALYSIS
FIGURE 41: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY END-USER SEGMENT
FIGURE 42: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY TYPE SEGMENT
FIGURE 43: ASIA PACIFIC BIOCHIPS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 44: CHINA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 45: JAPAN BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 46: INDIA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 47: SOUTH KOREA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 48: AUSTRALIA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 49: REST OF ASIA PACIFIC BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 50: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2017 (%)
COMPANIES MENTIONED
1. AGILENT TECHNOLOGY INC.
2. BIOCHAIN INSTITUTE INC.
3. BIOMERIEUX SA
4. BIO-RAD LABORATORIES INC.
5. CEPHEID INC.
6. CYBRDI INC.
7. FLUIDIGM CORPORATION
8. GAMIDA FOR LIFE GROUP
9. ILLUMINA INC.
10. IMGENEX
11. MERCK GMBH
12. ORIGENE TECHNOLOGIES INC.
13. PERKINELMER INC.
14. SAMSUNG ELECTRONICS INC.
15. THERMO FISHER SCIENTIFIC INC.
FIGURE 1: ASIA PACIFIC BIOCHIPS MARKET, BY END USERS, 2017 & 2026 (IN %)
FIGURE 2: ASIA PACIFIC BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 3: EVOLUTION & TRANSITION OF BIOCHIPS
FIGURE 4: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
FIGURE 5: COMPARISON OF HEALTHCARE SPENDING PER CAPITA AND OUT OF THE POCKET HEALTH EXPENDITURE
FIGURE 6: ASIA PACIFIC BIOCHIPS MARKET, BY DNA CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2018-2026 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2018-2026 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC DNA CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC DNA CHIPS MARKET, BY GENE EXPRESSION, 2018-2026 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC DNA CHIPS MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2018-2026 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC DNA CHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC BIOCHIPS MARKET, BY LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC LAB ON A CHIP MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS), 2018-2026 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC LAB ON A CHIP MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 20: ASIA PACIFIC LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC BIOCHIPS MARKET, BY PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 24: ASIA PACIFIC PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2018-2026 (IN $ MILLION)
FIGURE 25: ASIA PACIFIC PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2018-2026 (IN $ MILLION)
FIGURE 26: ASIA PACIFIC PROTEIN CHIPS MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 27: ASIA PACIFIC PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 28: ASIA PACIFIC BIOCHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 29: ASIA PACIFIC OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 30: ASIA PACIFIC OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 31: ASIA PACIFIC BIOCHIPS MARKET, BY GLASS, 2018-2026 (IN $ MILLIONS)
FIGURE 32: ASIA PACIFIC BIOCHIPS MARKET, BY POLYMERS, 2018-2026 (IN $ MILLIONS)
FIGURE 33: ASIA PACIFIC BIOCHIPS MARKET, BY SILICON, 2018-2026 (IN $ MILLIONS)
FIGURE 34: ASIA PACIFIC BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
FIGURE 35: ASIA PACIFIC BIOCHIPS MARKET, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2026 (IN $ MILLIONS)
FIGURE 36: ASIA PACIFIC BIOCHIPS MARKET, BY HOSPITALS AND DIAGNOSTICS CENTERS, 2018-2026 (IN $ MILLIONS)
FIGURE 37: ASIA PACIFIC BIOCHIPS MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2018-2026 (IN $ MILLIONS)
FIGURE 38: PORTER’S FIVE FORCE MODEL OF BIOCHIPS MARKET
FIGURE 39: VALUE CHAIN OF BIOCHIPS MARKET
FIGURE 40: KEY IMPACT ANALYSIS
FIGURE 41: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY END-USER SEGMENT
FIGURE 42: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY TYPE SEGMENT
FIGURE 43: ASIA PACIFIC BIOCHIPS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 44: CHINA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 45: JAPAN BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 46: INDIA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 47: SOUTH KOREA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 48: AUSTRALIA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 49: REST OF ASIA PACIFIC BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 50: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2017 (%)
COMPANIES MENTIONED
1. AGILENT TECHNOLOGY INC.
2. BIOCHAIN INSTITUTE INC.
3. BIOMERIEUX SA
4. BIO-RAD LABORATORIES INC.
5. CEPHEID INC.
6. CYBRDI INC.
7. FLUIDIGM CORPORATION
8. GAMIDA FOR LIFE GROUP
9. ILLUMINA INC.
10. IMGENEX
11. MERCK GMBH
12. ORIGENE TECHNOLOGIES INC.
13. PERKINELMER INC.
14. SAMSUNG ELECTRONICS INC.
15. THERMO FISHER SCIENTIFIC INC.
